United Therapeutics (NASDAQ:UTHR) had its price target boosted by Oppenheimer to $180.00 in a report released on Friday. The brokerage currently has an outperform rating on the biotechnology company’s stock.
Several other research firms have also recently weighed in on UTHR. Wedbush reissued an outperform rating and issued a $232.00 price objective (up from $213.00) on shares of United Therapeutics in a research report on Wednesday, December 27th. ValuEngine upgraded United Therapeutics from a buy rating to a strong-buy rating in a research note on Tuesday, December 26th. TheStreet upgraded United Therapeutics from a c+ rating to a b rating in a research note on Friday, December 15th. BidaskClub upgraded United Therapeutics from a sell rating to a hold rating in a research note on Wednesday, December 6th. Finally, Zacks Investment Research upgraded United Therapeutics from a strong sell rating to a hold rating in a research note on Monday, October 9th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. United Therapeutics currently has an average rating of Hold and a consensus target price of $138.50.
Shares of United Therapeutics (NASDAQ:UTHR) opened at $149.85 on Friday. United Therapeutics has a 12-month low of $112.01 and a 12-month high of $169.89. The firm has a market capitalization of $6,480.00, a P/E ratio of 13.21 and a beta of 1.41.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating the consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. During the same period in the prior year, the business earned $4.23 earnings per share. United Therapeutics’s revenue for the quarter was up 9.1% compared to the same quarter last year. equities analysts anticipate that United Therapeutics will post 12.96 EPS for the current fiscal year.
In other United Therapeutics news, Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $134.72, for a total transaction of $78,137.60. Following the completion of the transaction, the director now directly owns 1,555 shares in the company, valued at $209,489.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,269 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $118.04, for a total value of $149,792.76. Following the transaction, the chief executive officer now owns 1,409 shares of the company’s stock, valued at $166,318.36. The disclosure for this sale can be found here. Insiders sold 17,036 shares of company stock valued at $2,077,449 over the last 90 days. 7.80% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in UTHR. Victory Capital Management Inc. raised its stake in United Therapeutics by 20.9% during the second quarter. Victory Capital Management Inc. now owns 6,549 shares of the biotechnology company’s stock worth $850,000 after acquiring an additional 1,133 shares in the last quarter. Utah Retirement Systems raised its stake in United Therapeutics by 1.2% during the second quarter. Utah Retirement Systems now owns 8,165 shares of the biotechnology company’s stock worth $1,060,000 after acquiring an additional 100 shares in the last quarter. Principal Financial Group Inc. raised its stake in United Therapeutics by 3.9% during the second quarter. Principal Financial Group Inc. now owns 190,465 shares of the biotechnology company’s stock worth $24,709,000 after acquiring an additional 7,126 shares in the last quarter. Swiss National Bank grew its holdings in shares of United Therapeutics by 9.1% during the second quarter. Swiss National Bank now owns 164,000 shares of the biotechnology company’s stock worth $21,276,000 after purchasing an additional 13,700 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of United Therapeutics by 308.6% during the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock worth $64,930,000 after purchasing an additional 378,002 shares during the last quarter. Hedge funds and other institutional investors own 99.99% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Oppenheimer Boosts United Therapeutics (UTHR) Price Target to $180.00” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/09/oppenheimer-boosts-united-therapeutics-uthr-price-target-to-180-00.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.